clinical trials | pharmaphorum

Wednesday 23 September 2026

clinical trials

News

Boy in a wheelchair looking out to the forest

Regenxbio, Solid report data with Duchenne gene therapies

Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.

News

Immutep investors spooked by LAG-3 failure in lung cancer

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

BMS hq

BMS eyes another celmod filing in myeloma after phase 3 win

Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.

News

Roche's oral SERD flunks phase 3 breast cancer test

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

News

Adam Steensberg

Zealand hit as Roche-partnered obesity drug disappoints

Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.